Objective  To evaluate the application of novel oral anticoagulants (NOACs) in the treatment of elderly patients with non-valvular atrial fibrillation (NVAF), and to provide a basis for the rational use of drugs in clinical practice.

Methods  Based on the Beers criteria (2023 edition), combined with drug instructions and relevant guidelines, the potential inappropriate medication (PIM) evaluation criteria of NOACs in NVAF patients were formulated. The medication PIM of patients aged 80 years or older who were hospitalized in the cardiovascular department from January to December 2023 was analyzed when using NOACs.

Results  A total of 78 cases were included, and 47 cases of PIM occurred in NOACs, including 1 case of renal function-related PIM (2.13%), and 46 cases of drug interaction related PIM (97.87%). There were 72 patients who do not meet the evaluation criteria of the 2023 version of the Beers standard.

Conclusion  The updated Beers standard has not yet been widely adopted in clinical practice. The highest incidence of PIM in the use of NOACs in elderly patients with NVAF is due to drug interactions. It is necessary to strengthen drug monitoring in elderly patients with NVAF and promote rational drug use.

1.Sagris M, Vardas EP, Theofifilis P, et al. Atrial fibrillation: pathogenesis, predisposing factors, and genetics[J]. Int J Mol Sci, 2021, 23(1): 6. DOI: 10.3390/ijms23010006.

2.Calsolaro V, Okoye C, Antognoli R, et al. Long-term effectiveness and safety of anticoagulation therapy in oldest old, frail people with atrial fibrillation[J]. Eur J Intern Med, 2021, 86: 91-97. DOI: 10.1016/j.ejim.2021.01.020.

3.Bhatia HS, Hsu JC, Kim RJ. Atrial fibrillation and chronic kidney disease: a review of options for therapeutic anticoagulation to reduce thromboembolism risk[J]. Clin Cardiol, 2018, 41(10): 1395-1402. DOI: 10.1002/clc.23085.

4.Gunawardena T. Direct oral anticoagulants: a review for the non-specialist[J]. Hematol Rep, 2021, 13(4): 9239. DOI: 10.4081/hr.2021.9239.

5.Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation[J]. N Engl J Med, 2009, 361(12): 1139-1151. DOI: 10.1056/NEJMoa0905561.

6.Halperin JL, Hankey GJ, Wojdyla DM, et al. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF)[J]. Circulation, 2014, 130(2): 138-146. DOI: 10.1161/CIRCULATIONAHA.113.005008.

7.Granger CB, Alexander JH, Mcmurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation[J]. N Engl J Med, 2011, 365(11): 981-992. DOI: 10.1056/NEJMoa1107039.

8.Kato ET, Giugliano RP, Ruff CT, et al. Efficacy and safety of edoxaban in elderly patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial[J]. J Am Heart Assoc, 2016, 5(5): e003432. DOI: 10.1161/JAHA.116.003432.

9.张倩, 李沭, 李朋梅, 等. 美国老年医学会老年人潜在不适当用药Beers标准2023版解读[J]. 中国全科医学, 2023, 26(35): 4372-4381. [Zhang Q, Li S, Li PM, et al. Interpretation of the 2023 AGS Beers criteria: potentially inappropriate medication use in older adults[J]. Chinese General Practice, 2023, 26(35): 4372-4381.] DOI: 10.12114/j.issn.1007-9572.2023.0336.

10.Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin k antagonist oral anticoagulants in patients with atrial fibrillation[J]. Europace, 2021, 23(10): 1612-1676. DOI: 10.1093/europace/euab065.

11.《老年人心房颤动诊治中国专家建议》写作组, 中华医学会老年医学分会, 中国老年医学杂志编辑委员会. 老年人非瓣膜性心房颤动诊治中国专家建议（2016）[J]. 中华老年医学杂志, 2016, 35(9): 915-928. [Writing Committee for Expert Consensus on the Management of Atrial Fibrillation in Elderly Population, Chinese Geriatric Society, Editorial Board of Chinese Journal of Geriatrics. Expert consensus on the management of atrial fibrillation in elderly population(2016) [J]. Chin J Geriatr, 2016, 35(9): 915-928.] DOI: 10.3760/cma.j.issn.0254-9026. 2016.09.001.

12.中华医学会心电生理和起搏分会, 中国医师协会心律学专业委员会, 中国房颤中心联盟心房颤动防治专家工作委员会. 心房颤动: 目前的认识和治疗建议（2021）[J]. 中华心律失常学杂志, 2022, 26(1): 15-88. [Chinese Society of Pacing and Electrophysiology, Chinese Society of Arrhythmias, Atrial Fibrillation Center Union of China. Current knowledge and management of atrial fibrillation: consensus of Chinese experts 2021[J]. Chinese Journal of Cardiac Arrhythmias, 2022, 26(1): 15-88.] DOI: 10.3760/cma.j.cn113859-20211224-00264.

13.Wang Y, Hu G. Which renal function equation should be used for prescribing DOACs in patients with atrial fibrillation?[J]. JACC Asia, 2022, 2(1): 59-61. DOI: 10.1016/j.jacasi.2021.12.004.

14.Peng Y, Qi X, Guo X, et al. Child-Pugh versus MELD score for the assessment of prognosis in liver cirrhosis: a systematic review and Meta-analysis of observational studies[J]. Medicine (Baltimore), 2016, 95(8): e2877. DOI: 10.1097/MD.0000000000002877.

15.Aggarwal R, Ruff CT, Virdone S, et al. Development and validation of the DOAC score: a novel bleeding risk prediction tool for patients with atrial fibrillation on direct-acting oral anticoagulants[J]. Circulation, 2023, 19, 148(12): 936-946. DOI: 10.1161/CIRCULATIONAHA.123.064556.

16.Ersoy I. Novel drug interaction index and risk of mortality in older patients with atrial fibrillation receiving non-vitamin K oral anticoagulants (NOEL Drug)[J]. Clin App Thromb Hemost, 2021, 27: 10760296211038685. DOI: 10.1177/10760296211038685.

17.魏安华, 李文静, 黄妍. 某三甲医院达比加群酯潜在药物相互作用的回顾性研究[J]. 药物流行病学杂志, 2023, 32(11): 1243-1249. [Wei AH, Li WJ, Huang Y. A retrospective study of potential drug-drug interactions of dabigatran etexilate in a tertiary hospital[J]. Chinese Journal of Pharmacoepidemiology, 2023, 32(11): 1243-1249.] DOI: 10.19960/j.issn.1005-0698. 202311007.

18.Cohen AT, Hamilton M, Mitchell SA, et al. Comparison of the novel oral anticoagulants apixaban, dabigatran, edoxaban, and rivaroxaban in the initial and long-term treatment and prevention of venous thromboembolism: systematic review and network meta-analysis[J]. PLoS One, 2015, 10 (12) : e0144856. DOI: 10.1371/journal.pone.0144856.

19.Bai Y, Deng H, Shantsila A, et al. Rivaroxaban versus dabigatran or warfarin in real-world studies of stroke prevention in atrial fibrillation: systematic review and Meta-analysis[J]. Stroke, 2017, 48(4): 970-976. DOI: 10.1161/STROKEAHA.116.016275.

20.Lip GYH, Kotalczyk A, Teutsch C, et al. Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF registry[J]. Clin Res Cardiol, 2022, 111(5): 560-573. DOI: 10.1007/s00392-022-01996-2.

21.Deitelzweig S, Keshishian A, Li X. Comparisons between oral anticoagulants among older nonvalvular atrial fibrillation patients[J]. J Am Geriatr Soc, 2019, 67(8): 1662-1671. DOI: 10.1111/jgs.15956.

22.程芳, 郝倩, 司海娇, 等. 高龄老年非瓣膜性房颤患者应用新型口服抗凝药物的情况分析[J]. 空军医学杂志, 2020, 36(4): 355-357. [Cheng F, Hao Q, Si HJ, et al. Analysis of the application of novel oral anticoagulants in elderly patients with non-valvular atrial fibrillation[J]. Medical Journal of Air Force, 2020, 36(4): 355-357.] DOI: 10.3969/j.issn.2095-3402.2020.04.024.

23.Schäfer A, Flierl U, Berline D. Anticoagulants for stroke prevention in atrial fibrillation in elderly patients[J]. Cardiovasc Drugs Ther, 2020, 34(4): 555-568. DOI: 10.1007/s10557-020-06981-3.

24.Magnocavallo M, Bellasi A, Mariani MV, et al. Thromboembolic and bleeding risk in atrial fibrillation patients with chronic kidney disease: role of anticoagulation therapy[J]. J Clin Med, 2020, 10(1): 83. DOI: 10.3390/jcm10010083.

25.Carrero JJ, Trevisan M, Sood MM, et al. Incident atrial fibrillation and the risk of stroke in adults with chronic kidney disease: the Stockholm CREAtinine Measurements (SCREAM) project[J]. Clin J Am Soc Nephrol, 2018, 13(9): 1314-1320. DOI: 10.2215/CJN.04060318.

26.王凯, 刘元生, 高伟波, 等. 肾功能衰竭患者心房颤动的抗凝治疗进展[J].中国血液净化, 2018, 17(7): 472-475. [Wang K, Liu YS, Gao WB, et al. Progress in anticoagulant therapy for atrial fibrillation in patients with renal failure[J]. Chinese Journal of Blood Purification, 2018, 17(7): 472-475.] DOI: 10.3969/j.issn.1671-4091.2018.07.010.

27.Lisman T, Kamphuisen PW, Northup PG, et al. Established and new-generation antithrombotic drugs in patients with cirrhosis: possibilities and caveats[J]. J Hepatol, 2013, 59(2): 358-366. DOI: 10.1016/j.jhep.2013.03.027.

28.Fuentes A, Gordon-burroughs S, Hall JB, et al. Comparison of anti-Ⅹa and activated partial thromboplastin time monitoring for heparin dosing in patients with cirrhosis[J]. Ther Drug Monit, 2015, 37(1): 40-44. DOI: 10.1097/FTD.0000000000000105.